A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S., Chandana, S. R., Rasco, D. W., Colevas, A., O'Rourke, T. J., Papadopoulos, K. P., Fisher, G. A., Chao, M., Agoram, B., Chen, J. Y., Huang, J., Axt, M., Majeti, R., Weissman, I. L., Takimoto, C. M., Pegram, M. D., Padda, S. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.3002

View details for Web of Science ID 000442916001377